Long Acting Injectables Market, By Indication (Psychiatric disorders, Neurological disorders, Endocrine and metabolic disorders, Infectious diseases, Women’s health, Oncology and supportive care, Pain, addiction and CNS supportive care, and Other chronic diseases), By Molecule Type (Small-molecule drugs (Antipsychotics, Hormonal agents, Analgesics and addiction therapies, and Other small-molecule LAIs), Peptides and peptide analogues (GLP-1 and related incretin mimetics and Other therapeutic peptides), Proteins and biologics, (Monoclonal antibodies, Fusion proteins and recombinant hormones, and Long-acting growth factors and cytokines), Nucleic acid–based and gene-modifying agents (Oligonucleotides and Gene therapy linked depot systems), Vaccines and immunotherapies in LAI formats, and Other molecule types), By Route of Administration (Intramuscular, Subcutaneous, Intravitreal, Intra-articular, Intrathecal and epidural, and Other specialized parenteral routes), By Device Format (Pre-filled Syringes, Auto-injectors, Vial and Syringe Kits, Implant Kits, and Pen-injector LAI Systems), By Formulation Technology (Microsphere-based Depots, In-situ Forming Depots, Liposomal LAIs, Nano-suspensions, Polymer-conjugated LAIs, Implantable LAI Devices, Oil-based Injectable Depots, and Long-acting Injectable Crystalline Suspensions), By Patient Type (Adult, Geriatric, and Pediatric), By End User (Hospitals, Specialty Clinics, Community Health Centers, Ambulatory Surgical Centers, Home-care/Self-administration Programs, and Government and Public Health Programs), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), By Payer (Public and Private), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Growth Trends and Forecasts (2025-2032)